Recombinant human adenoviruses (Ads) (types 4, 5, and 
AIDS has been linked etiologically with the HIV-1 by various investigators (1) (2) (3) . Numerous approaches to producing a safe and efficacious vaccine for HIV have been pursued by several laboratories, ranging from employment of whole inactivated virus (4) to using recombinant protein subunit preparations (5) . The development and progress of various HIV vaccines has recently been reviewed (6) . The major HIV antigen targeted for use in vaccines is the membraneassociated envelope glycoprotein gpl60 or one of its cleavage products, gpl20. Recombinant virus-vectored vaccines, primarily using vaccinia virus, have been tested in chimpanzees (7) and in human clinical studies (8) . These recombinant viruses were demonstrated to induce seroconversion to the HIV envelope antigen and cell-mediated immune responses, as measured by antigen-specific proliferation assays, in both chimpanzees and humans. However, they failed to produce high-titer neutralizing responses and did not protect chimpanzees from challenge with infectious HIV-1 (7) .
Human adenovirus (Ad) has received increasing attention as a potential vector for recombinant viral vaccines. Recently, Ad-vectored recombinant vaccines have been constructed using key viral genes from a variety ofanimal viruses (9, 10) . Advantages of recombinant Ad-vectored vaccines include (i) safety [human Ad vaccines, types 4 and 7, have proven safe and efficacious during use in military recruits for >30 years] and (ii) the antigenic diversity of Ads (>45 serotypes described), which may allow exploitation of antigenically distinct vectors for multiple sequential booster immunizations.
In vivo analysis of recombinant Ad vaccines has been difficult due to the extreme host-range restriction of human Ads. Ad5-vectored vaccines have been tested in hamsters and cotton rats, but these models are not permissive for Ad4 and Ad7 recombinants. Ad5-HIV vectors expressing the gp160 were tested for immunogenicity in cotton rats (11) . We have since reported the enhancement of envelope expression mediated by coexpression of the rev gene by using recombinant Ad7 vectors in vitro (12) . In the present study, in addition to the Ad7 recombinant, we have also made use of an Ad4-env and an Ad5-env recombinant. All recombinant viruses described in this report contain the HIV rev regulatory gene. Two additional animal models have been described for evaluation of recombinant Ad4 and Ad7: the chimpanzee, the only permissive model for oral-enteric Ad infection (13) , and the laboratory beagle, which undergoes a semipermissive or abortive infection after deposition of virus in the lung by intratracheal inoculation (14) . Unfortunately, the chimpanzee is not a practical animal model for initial testing and screening of recombinant viruses due to a lack of availability and high expense. In contrast, the beagle has proven useful for evaluating humoral immune responses to foreign viral antigens in spite of its low permissivity for human Ads (14) . In this report, the dog model has been employed to show that sequential administration of serologically distinct recombinant Ads was effective in eliciting strong humoral responses to HIV envelope glycoprotein, including high-titer neutralizing antibodies. Furthermore, we demonstrate that recombinant envelope produced in the Ad system effectively boosts immune responses primed by live recombinant Ads.
MATERIALS AND METHODS
Construction of Recombinant Ads. The procedure for generation of recombinant Ads has been described (12) . To confirm the DNA structure of each recombinant, DNAs were extracted by the method of Hirt (15) HIV-1 Neutralization. The assay for neutralization of cellfree HIV has been described (18) . H9 cells (1) were used as targets for infection, and either a frozen titered stock of HIV-1/HTLV-IIIB (1) or fresh HIV-1/HTLV-IIIMN (2, 19) from culture supernatant were the infecting viruses. Endpoint titers were defined as the reciprocal of the serum dilution at which infectivity levels were 60%o of control values after normalization of the data to control infectivity levels.
Adenovirus Microneutlizatlon Assay. Type-specific neutralizing antibody activity was determined using A549 cell monolayers as described (14) . Titers were expressed as the reciprocal of the lowest dilution at which 50% cytopathic effect was observed.
RESULTS

Virus Construction and Expression of HIV-env in Tissue
Culture. Recombinant Ads were generated that contained the gpl60 HIV envelope gene along with a copy of the rev gene. These recombinant viruses maintained the foreign DNA in a stable fashion. All constructs expressed roughly the same amount of recombinant envelope antigen, 2-5 ,ug per 106 cells. There were no significant differences in the growth kinetics of these viruses (data not shown).
Humoral Responses to Ads. Intratracheal inoculation of dogs with recombinant Ad7-env viruses ( Proc. Natl. Acad. Sci. USA 89 (1992) Syntex supplemented with T-MDP. All recombinant envelope subunit preparations were demonstrated by Western blot analysis to boost antibody responses to gpl60, gpl20, and gp4l (Fig. 2) . Syntex adjuvant induced the highest immune responses, with gpl60 reactivity detected at a serum dilution of 1:10,000.
After the subunit booster injection, neutralizing antibody titers also rose significantly (Table 2 ). In dogs inoculated with Ad7-env recombinant, after the first booster injection with Ad4-env, neutralizing antibodies were elicited in 9 of 11 dogs with titers ranging from 30 to 780. These titers declined over the subsequent 10 weeks, although in general neutralizing activity could still be detected. The booster injection with gp120/gpl6O subunit resulted in restoration of neutralizing antibody activity, with 7 of 11 dogs exhibiting higher titers than those seen after the Ad4-env booster injection. In fact, dogs 226 and 168, which failed to display significant neutralizing activity after the Ad4-env booster injection, demonstrated good neutralizing activity after the booster injection with envelope subunit, indicating that they had been primed by the recombinant immunizations. Dogs that received the subunit booster injection in Syntex plus T-MDP (dogs 211, 183, 169, and 226) or in alum plus deoxycholate (dogs 215, 187, 170, and 168) exhibited greater increases in neutralizing antibody titers compared to dogs who received the envelope booster injection formulated in alum alone (dogs 1%, 204, and 208). Dog 206, which received a primary immunization of Ad7-env recombinant followed by the envelope subunit in alum with no intervening Ad4-env recombinant booster injection, failed to seroconvert to envelope antigen (Fig. 2) or to develop neutralizing activity (data not shown). Table 2 also illustrates that after immunization with two Ad recombinants and an envelope subunit booster injection, all 11 dogs exhibited antibodies by a peptide ELISA to the V3 loop of HIVIIIB. The V3 region has been shown to elicit predominantly type-specific neutralizing antibodies (20) , and in fact type-specific neutralization ofonly the IRIB isolate and not MN was observed (data not shown).
After a period of -'7 months, these same animals were given another booster injection with an envelope subunit in alum consisting of either gpl20 of the ITB strain, expressed in the Ad or the baculovirus system, or of the MN strain, purified from cultures ofproductively infected human T cells. At the time of this inoculation, neutralizing antibodies could be detected in only 5 of the dogs. Two to 4 weeks after this booster, however, neutralizing antibodies could be observed in 9 of the 11 dogs, although they did not reach levels observed previously ( Table 2 ). The best boosting effect was seen in dog 1%, which received as subunit MN gpl20. Not only did this heterologous protein boost the neutralizing antibody titer against the TIB isolate, it also elicited low neutralizing activity (titer of 1: 20) 
DISCUSSION
In this study recombinant HIV vaccines were constructed using as vectors Ad4, Ad7, and AdS vaccine strains that had 12 weeks after the first booster immunization. Sera collected 1 week prior to (-1) and 2 weeks after subunit booster immunization were tested as described in Fig. 1 . A human aHIV anti-serum was used to detect the positions of the HIV glycoproteins gpl60, gpl20, and gp4l. Lane labels indicate the time (weeks) after the booster injection, the number of the dog, and the adjuvant used.
been safety-tested in humans. Recombinant viruses contained the entire envelope gene and a copy of the rev regulatory gene, which has been demonstrated to enhance expression of gpl60 in the recombinant Ad system (12) .
Other investigators have reported that the Ad5-HIV recombinant virus that expresses HIV envelope gpl60 (E3 region deletion and insertion) induces anti-envelope antibodies in cotton rats after intranasal inoculation (11) . Although antibody responses were detected by ELISA and Western blot analysis, neutralizing antibody responses were not reported. However, in the present study, Ad-HIV recombinant viruses in the dog have elicited potent type-specific neutralizing antibody responses. Heterotypic booster immunizations with a second Ad-HIV recombinant virus were required to obtain optimal immune responses. We also demonstrated that gpl20/gpl60 preparations derived from Ad7-env recombinant virus-infected cells effectively boosted anti-envelope antibody responses in dogs previously immunized with Ad-HIV recombinants. However, anti-HIV neutralizing antibody activity was boosted significantly only in dogs that received two immunizations with Ad-HIV recombinants prior to subunit administration. In addition, the timing of these booster injections was important. While a schedule of immunization every 3 months resulted in high neutralizing antibody activity, a hiatus of 7 months before a second subunit inoculation resulted in generally low neutralizing antibody titers. Human Ads have a very restricted host range and infect the dog poorly, undergoing an abortive infection. It will be crucial to test whether improved priming by Ad recombinants with resultant improvement of immunologic memory occurs in a more permissive host such as the chimpanzee and ultimately humans.
The immunological mechanism(s) responsible for protection against HIV infection continues to remain uncertain. Whereas some aspect of cell-mediated immunity (such as cytotoxic T-cell activity) would be expected to be essential for elimination of HIV-infected cells, the development of humoral immunity to HIV would be expected to play a critical role in protection against infection, spread, and clearance of cell-free virus. Due to the demonstrated antigenic diversity among HIV isolates worldwide, it is obvious that induction of a neutralizing antibody response that recognizes group-specific epitopes would be highly desirable. The envelope glycoprotein has been identified as the primary target of neutralizing antibodies and has been shown to contain both group-and type-specific determinants. Others have shown that type-specific neutralizing antibody can protect chimpanzees from challenge with cell-free HIV (21) . The same investigators demonstrated protection of chimpanzees that were immunized with recombinant gp120. A principal neutralization determinant has been identified in the third variable loop of the gpl20 portion of the envelope gene (22) . Neutralizing antibodies directed against the principal neutralization determinant appear for the most part to be type-specific, although 60%o of HIV-1 isolates examined in one study were demonstrated to contain a conserved sequence ofGly-Pro-Gly-Arg-Ala-Phe within the principal neutralization determinant (23) . Certain strains, such as the MN isolate, appear to be serologically more related to the majority of U.S. field isolates than other strains, such as the LAV isolate (24). It therefore might be possible to use a single isolate such as the MN strain to produce an effective vaccine that will protect across a wide spectrum of HIV strains. In this regard, it is of interest that in one dog, inoculation of the MN envelope protein boosted the neutralizing antibody against the original immunizing strain IIIB and also resulted in low-titer neutralizing antibody to the MN isolate itself (Table 2 ). This may reflect immunologic recognition in this animal of the shared tip of the V3 loop, resulting in broadening of immunologic specificity. Alternatively, a mixture of several strains possessing antigenically diverse envelope antigens may be necessary to induce broad protection. The Dogs were immunized intratracheally with recombinant viruses or injected subcutaneously with Ad-derived recombinant gpl20/gpl60 (r-env) in 0.2% alum. Booster inoculations were administered 12 weeks after the primary immunizations. Sera were collected 2 weeks after booster immunizations and titered. The data for the eight dogs immunized with Ad4-env and Ad5-env viruses are derived from Table 1. recombinant Ad system can be adapted to express numerous envelope antigens by insertion of different envelope genes into separate vectors ofthe same serotype. Furthermore, this system has the potential advantage of boosting the immune response to recombinant antigen by administration of heterotypic recombinant Ads.
In summary, we have examined the potential of the recombinant Ad system for delivery and presentation of the HIV envelope antigen. This system can be manipulated to elicit high-titer type-specific antibody responses to HIV isolates by using booster injections of heterotypic recombinant viruses expressing the same recombinant envelope glycoprotein. We have also demonstrated that recombinant Ads are capable of inducing high-titer neutralizing antibodies directed at the envelope antigen. However, in addition to the generation of a potent humoral antibody response to HIV antigens, we believe that it is also likely that replicating recombinant Ad will effectively induce cell-mediated immune responses. However, further work is required to address the problem ofinducing a broader neutralizing antibody response that will recognize a variety of HIV isolates.
